Zynex Inc ZYXI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ZYXI is a good fit for your portfolio.
News
-
Zynex to Present at the RBC Capital Markets Global Healthcare Conference
-
Zynex Executives Recognized Among Top 25 in Medical Technology
-
Zynex Reports First Quarter 2024 Financial Results
-
Zynex Sets First Quarter 2024 Earnings Call
-
Zynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition Award
Trading Information
- Previous Close Price
- $9.92
- Day Range
- $9.87–10.20
- 52-Week Range
- $6.88–13.77
- Bid/Ask
- $9.91 / $10.23
- Market Cap
- $322.52 Mil
- Volume/Avg
- 137,754 / 149,442
Key Statistics
- Price/Earnings (Normalized)
- 39.57
- Price/Sales
- 1.88
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 14.84%
Company Profile
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
- Sector
- Healthcare
- Industry
- Medical Distribution
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,101
- Website
- https://www.zynex.com
Comparables
Valuation
Metric
|
ZYXI
|
OM
|
PEN
|
---|---|---|---|
Price/Earnings (Normalized) | 39.57 | — | 127.16 |
Price/Book Value | 9.91 | 2.12 | 6.10 |
Price/Sales | 1.88 | 1.53 | 6.79 |
Price/Cash Flow | 29.45 | — | 41.13 |
Price/Earnings
ZYXI
OM
PEN
Financial Strength
Metric
|
ZYXI
|
OM
|
PEN
|
---|---|---|---|
Quick Ratio | 2.68 | 4.27 | 3.31 |
Current Ratio | 3.58 | 5.26 | 6.12 |
Interest Coverage | 8.22 | −13.39 | — |
Quick Ratio
ZYXI
OM
PEN
Profitability
Metric
|
ZYXI
|
OM
|
PEN
|
---|---|---|---|
Return on Assets (Normalized) | 6.70% | −38.44% | 6.00% |
Return on Equity (Normalized) | 17.18% | −83.38% | 7.99% |
Return on Invested Capital (Normalized) | 8.69% | −43.78% | 6.20% |
Return on Assets
ZYXI
OM
PEN
Medical Distribution Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
MCK
| McKesson Corp | Sdmdrxkl | Zshzp | $72.6 Bil | |
COR
| Cencora Inc | Btlrdrxx | Llhjlm | $44.6 Bil | |
CAH
| Cardinal Health Inc | Kcrrjmq | Lktryg | $23.4 Bil | |
SHPMF
| Shanghai Pharmaceuticals Holding Co Ltd Class H | — | Cvqhjs | $8.5 Bil | |
SHPMY
| Shanghai Pharmaceuticals Holding Co Ltd ADR repr Class H | — | Dmmjdc | $8.5 Bil | |
SHTDF
| Sinopharm Group Co Ltd | — | Dlvjvxk | $8.5 Bil | |
SHTDY
| Sinopharm Group Co Ltd ADR | — | Rftdrb | $8.5 Bil | |
AMFPF
| Amplifon SpA Az nom Post Frazionamento | — | Mwkrkt | $8.3 Bil | |
MAHLY
| Medipal Holdings Corp ADR | — | Tvvp | $3.1 Bil | |
MEPDF
| Medipal Holdings Corp | — | Vwsk | $3.1 Bil |